《大行報告》匯豐研究下調中生製藥(01177.HK)目標價至9.87元 評級「買入」
匯豐研究發表報告表示,中生製藥(01177.HK)股價自去年7月起累跌約20%,去年度經營利潤低於該行預期24%,惟在新藥推出下,料中生製藥今明兩年增長回復至雙位數,估計其藥物業務於2021至2023年度每股盈利年複合增長率為17%,而且公司於腫瘤學及呼吸領域的強勁發展勢頭。
該行下調其今明兩年收益預測分別13%及11%,降純利盈測分別19%及17%,以反映仿製藥收入下降,擴展費用增加及公司會計政策變更等因素,目標價由11.3元降至9.87元,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.